Oncology Archives - WuXi Biology

Poster Presentations at AACR 2026

At AACR 2026, scientists from our WuXi Biology platform will present a collection of the company’s latest oncology research findings...

Supporting Discovery of mRNA Drugs

Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...

mTOR Inhibition Enhances Targeted Protein Degradation Efficacy

Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...

ALDH1A2 Inhibition Enhances Antitumor DC Vaccine Efficacy

Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...

KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...

R&D Strategies for T Cell Engager Drugs

From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Solving the Complexities of T Cell Engager Development

T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...

Radionuclide Drug Conjugates in Anticancer Treatment

Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...

Knowledge Library